Granted Patent
B2
US 9,561,263 · App. 12/808,818 · Granted Feb 7, 2017
Treatment of inflammatory illnesses with ACE2
Assignee:
Apeiron Biologics AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.
Claims (3)
1. A method of treating sepsis in a human subject in need thereof, comprising administering to a human patient in need thereof a water-soluble, recombinant, human angiotensin converting enzyme 2 (ACE2) polypeptide wherein said water-soluble, recombinant, human ACE2 polypeptide comprises amino acids 18-615 of SEQ ID NO:1, said ACE2 polypeptide is administered systemically.
2. The method of claim 1 , wherein the ACE2 polypeptide comprises a polypeptide comprising amino acids 18 to 740 of SEQ ID No:1.
3. The method of claim 2 , wherein the ACE2 polypeptide is glycosylated and has a sugar content of greater than 20% by weight of the total ACE2.
Assignments (3)
SECURITY INTEREST
Recorded Dec 23, 2024
From: APEIRON BIOLOGICS GMBH
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 069669/0908 →
CHANGE OF NAME
Recorded Dec 10, 2024
From: APEIRON BIOLOGICS AG
To: APEIRON BIOLOGICS GMBH
Reel/Frame 069584/0365 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 20, 2016
From: LOIBNER, HANS; SCHUSTER, MANFRED
To: APEIRON BIOLOGICS AG
Reel/Frame 040680/0375 →
Priority Claims (1)
AT A 2058/2007
· Dec 18, 2007
· national
Continuity (1)